Maxim Plans To File Maxamine Malignant Melanoma NDA By Mid-2000
Executive Summary
Maxim is targeting a mid-2000 NDA filing for its malignant melanoma immunotherapy Maxamine, which will be followed by European regulatory applications, Maxim CEO Larry Stambaugh told a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.